![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H28FNO |
Molar mass | 329.459 g·mol−1 |
3D model (JSmol) | |
| |
|
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB1 and CB2 with EC50 values of 98 nM and 83 nM, respectively. [2] It is a 3-(tetramethylcyclopropylmethanoyl)indole derivative related to compounds such as UR-144, A-796,260 and A-834,735, but it is not specifically listed in the patent or scientific literature alongside these other similar compounds, [3] [4] and appears to have not previously been made by Abbott Laboratories, despite falling within the claims of patent WO 2006/069196. XLR-11 was found to produce rapid, short-lived hypothermic effects in rats at doses of 3 mg/kg and 10 mg/kg, suggesting that it is of comparable potency to APICA and STS-135. [2]
A forensic standard for this compound is available, and a representative mass spectrum has been posted on Forendex. [5]
XLR-11 was instead first identified by laboratories in 2012 as an ingredient in synthetic cannabis smoking blends, and appears to be a novel compound invented specifically for grey-market recreational use. [6]
XLR-11 was banned in New Zealand by being added to the temporary class drug schedule, as of 13 July 2012 [update] . [7]
The U.S. Drug Enforcement Administration (DEA) made XLR11 illegal under the Federal Controlled Substances act for the foreseeable future as of January 2024 [update] . [8]
It has also been banned in Florida as of 11 December 2012 [update] . [9]
Arizona banned XLR-11 on 3 April 2013. [10]
As of October 2015 [update] , XLR-11 is a controlled substance in China. [11]
XLR-11 has been linked to hospitalizations due to its use. [13]
XLR-11 has been linked to acute kidney injury in some users, [14] along with AM-2201. [15] [16]